Drugs / CANERTINIB
CANERTINIB
also known as
CI 1033 · CANERTINIB (CI-1033) · CANERTINIB DIHYDROCHLORIDE · Canertinib hydrochloride · GW781483X · PD-0183805 · PD-0183805-002B · PD-183805 · +1 more
Small molecule targets EGFR, ERBB2, ERBB4 via inhibition
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00174356 | Dec 2002 → Oct 2005 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00050830 | Jan 2003 → Nov 2005 | lung neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00051051 | Dec 2002 → May 2005 | breast cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANERTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | CANERTINIB (CI-1033) | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | CANERTINIB DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | Canertinib hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | CI 1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00050830 ↗ |
| Known as | GW781483X | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | PD-0183805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | PD-0183805-002B | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | PD-183805 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Known as | SN-26606 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31965 ↗ |
| Action | Inhibit | “Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL31965 ↗2“Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL31965 ↗ “acts as an inhibitor of erbB (EGFR) receptors” NCT00051051 ↗ |
| Modality | Small molecule | — CHEMBL31965 ↗ |
| Route | Oral | “CI-1033 is administered orally.” NCT00051051 ↗ |
| Target | EGFR | “acts as an inhibitor of erbB (EGFR) receptors” NCT00051051 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL31965 ↗ |
| Target | ERBB4 | “Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL31965 ↗ |